Search Results - (Author, Cooperation:Glicksman)

Otolaryngology–Head and Neck Surgery, Wiley, Vol. 165, No. 3 ( 2021-09), p. 424-430

Coronavirus disease 2019 (COVID‐19) significantly affected many health care specialties, including otolaryngology. In response to governmental policy changes, many hospitals and private practices in Massachusetts canceled or postponed nonurgent office visits and elective surgeries. The objective of this study was to quantify the impact of COVID‐19 on the provision and practice trends of otolaryngology services for 10 private practices in Massachusetts. Study Design Retrospective review. Setting Multipractice study for community practices in Massachusetts. Methods Electronic billing records from 10 private otolaryngology practices in Massachusetts were obtained for the first 4 months of 2019 and 2020. Questionnaires from these otolaryngology practices were collected to assess financial and staffing impact of COVID‐19. Results The local onset of the COVID‐19 pandemic had a significant decrease of 63% of visits in comparison to equivalent weeks in 2019. Virtual visits overtook in‐person visits over time. A greater decline in operating room (OR) procedures than for office procedures was recorded. Ninety percent of practices reduced working hours, and 80% furloughed personnel. Seventy percent of practices applied for the Paycheck Protection Program (PPP). Conclusion COVID‐19 has had a multifaceted impact on private otolaryngology practices in Massachusetts. A significant decline in provision of otolaryngology services aligned with the Massachusetts government’s public health policy changes. The combination of limited personnel and personal protective equipment, as well as suspension of nonessential office visits and surgeries, led to decrease in total office visits and even higher decrease in OR procedures.

Online Resource

0194-5998, 1097-6817

English

Wiley

2021

2008453-5

New England Journal of Medicine, Massachusetts Medical Society, Vol. 388, No. 1 ( 2023-01-05), p. 84-88

Online Resource

0028-4793, 1533-4406

English

Massachusetts Medical Society

2023

1468837-2

Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 23, No. 16_suppl ( 2005-06), p. 9645-9645

Online Resource

0732-183X, 1527-7755

English

American Society of Clinical Oncology (ASCO)

2005

2005181-5

Journal of Cellular Plastics, SAGE Publications, Vol. 28, No. 3 ( 1992-05), p. 268-283

Online Resource

0021-955X, 1530-7999

English

SAGE Publications

1992

2098525-3

2

Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 39, No. 6_suppl ( 2021-02-20), p. 241-241

241 Background: Stereotactic body radiotherapy (SBRT) is increasingly used to treat patients with intermediate-risk prostate cancer (IR-PCa), but there is a lack of early surrogate measures in this patient population treated with SBRT to guide clinicians and patients. We aim to explore the outcomes of IR-PCa patients treated with SBRT and to assess the role of PSA response at 4 years (4yPSARR) as an early surrogate measure given its encouraging results in patients treated with brachytherapy. Methods: Individual patient data from 6 institutions for 820 patients with IR-PCa treated with SBRT between 2006 and 2014 were analyzed. Cumulative incidence of biochemical recurrence (defined by Phoenix criteria) was calculated using Nelson-Aalen estimates, and metastases-free survival and overall survival were calculated using the Kaplan-Meier method. Biochemical recurrence-free survival was analyzed according to 4yPSARR with groups dichotomized based on PSA 〈 0.4 ng/mL or 〉 0.4 ng/mL and compared using Log-rank test. Results: 820 patients were included, including 549 (67%) with favorable intermediate and 271 (33%) with unfavorable intermediate risk disease defined by NCCN risk group classification. Median age at time of treatment was 70 years. The most common dose, fractionation and treatment schedule was 36.25 Gy in 5 fractions prescribed to the planning target volume delivered every other day. Androgen deprivation therapy was used in combination with SBRT in 9.2% of patients for a median duration of 3 months. Median follow-up was 5.9 years. The cumulative incidence of biochemical recurrence was 7.9% at 5 years. Metastases-free survival and overall survival rates at 5 years were 99.4% and 94.6%, respectively. Median 4yPSARR (n = 504) was 0.2 ng/mL. Biochemical recurrence-free survival in patients with 4yPSARR 〈 0.4 ng/mL (n = 387) was 99.2%, and in patients with 4yPSARR 〉 0.4 ng/mL (n = 117) was 81.5% at 5 years (p 〈 0.0001). Conclusions: Prostate SBRT is an effective treatment modality in men with IR-PCa with at least comparable rates of biochemical failure and metastases compared to other standard treatment modalities in patients with IR-PCa. 4yPSARR may represent an early surrogate measure for use in this patient population treated with SBRT and should be included for further study in prospective SBRT trials.

Online Resource

0732-183X, 1527-7755

English

American Society of Clinical Oncology (ASCO)

2021

2005181-5

Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 41, No. 6_suppl ( 2023-02-20), p. 410-410

410 Background: Between 4%- 30% of patients with clinical stage 1 (CS I) seminoma testis (ST) in active surveillance (AS) relapse depending on pathological risk factors tumor size (TS) and rete testis invasion (RTI). The level of evidence supporting these pathological risk factors in clinical decision-making is low due to heterogeneous study design and reporting and the difficulty to analyze patient subgroups according to combination of these factors. The objectives of the present study were to identify the most important pathological prognostic factors predicting relapse in CS I seminoma patients with normal post-orchidectomy serum tumor marker (STM) levels in AS and to construct risk-groups for guiding treatment decision-making and follow-up. Methods: Individual patient data from 1016 CS I-ST patients diagnosed between February 1994 and January 2019 in AS were collected from 9 institutions. Central pathology review was not routinely performed in all institutions; therefore, pagetoid and stromal RTI were not differentiated explicitly in most cases. Assessing patient age, pre-orchidectomy STM b-human chorionic gonadotropin and lactate dehydrogenase, pathological TS, RTI, lympho-vascular invasion (LVI), multi-focality, and GCNIS, multivariable Cox proportional hazards regression models were fit to identify the most important prognostic factors for the time to first relapse by imaging and/or markers (primary endpoint). Probabilities of relapse were estimated using Kaplan-Meier curves. Results: After median follow-up of 7.7 years, 149 (14.7%) patients relapsed, 104 identified by imaging alone, 44 by imaging with elevated STMs and 1 by elevated STMs alone. Excluding 18 patients with unknown LVI from the multivariable analyses, TS (≤ 2 cm, between 2 and 5 cm, 〉 5 cm), presence of RTI and presence of LVI were used to form three risk groups: very low, low and high-risk (Table). Five-years probability of relapse varied from 8% in the very low risk-group to 44% in the high risk-group. The new model outperformed the current model with TS 〈 4cm vs ≥ 4 and RTI (Harrell's C index 0.65 vs 0.61) and identifies a subgroup of patients with a higher risk of relapse. Conclusions: The new risk-group stratification for CS I -ST patients in AS outperforms the histopathological model based on TS and RTI. It will serve to better inform patients on the risk of relapse during follow-up after orchidectomy but requires an independent validation. [Table: see text]

Online Resource

0732-183X, 1527-7755

English

American Society of Clinical Oncology (ASCO)

2023

2005181-5

International Journal of Radiation Oncology*Biology*Physics, Elsevier BV, Vol. 42, No. 1 ( 1998-08), p. 125-135

Online Resource

0360-3016

English

Elsevier BV

1998

1500486-7

International Journal of Radiation Oncology*Biology*Physics, Elsevier BV, Vol. 12, No. 8 ( 1986-8), p. 1423-1427

Online Resource

0360-3016

English

Elsevier BV

1986

1500486-7

International Journal of Radiation Oncology*Biology*Physics, Elsevier BV, Vol. 7, No. 11 ( 1981-11), p. 1561-1568

Online Resource

0360-3016

English

Elsevier BV

1981

1500486-7

International Journal of Radiation Oncology*Biology*Physics, Elsevier BV, Vol. 4 ( 1978-10), p. 162-

Online Resource

0360-3016

English

Elsevier BV

1978

1500486-7

International Journal of Radiation Oncology*Biology*Physics, Elsevier BV, Vol. 8, No. 5 ( 1982-5), p. 937-939

Online Resource

0360-3016

English

Elsevier BV

1982

1500486-7

International Journal of Radiation Oncology*Biology*Physics, Elsevier BV, Vol. 30, No. 5 ( 1994-12), p. 1043-1050

Online Resource

0360-3016

English

Elsevier BV

1994

1500486-7

Surgical Endoscopy, Springer Science and Business Media LLC, Vol. 26, No. 2 ( 2012-2), p. 442-450

Online Resource

0930-2794, 1432-2218

English

Springer Science and Business Media LLC

2012

1463171-4

Brain Research, Elsevier BV, Vol. 188, No. 1 ( 1980-04), p. 53-62

Online Resource

0006-8993

English

Elsevier BV

1980

1462674-3

12

International Journal of Radiation Oncology*Biology*Physics, Elsevier BV, Vol. 7, No. 7 ( 1981-7), p. 943-947

Online Resource

0360-3016

English

Elsevier BV

1981

1500486-7

International Journal of Radiation Oncology*Biology*Physics, Elsevier BV, Vol. 7, No. 9 ( 1981-9), p. 1248-

Online Resource

0360-3016

English

Elsevier BV

1981

1500486-7

International Journal of Radiation Oncology*Biology*Physics, Elsevier BV, Vol. 23, No. 5 ( 1992-1), p. 1079-1082

Online Resource

0360-3016

English

Elsevier BV

1992

1500486-7

International Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine, Informa UK Limited, Vol. 43, No. 3 ( 1983-01), p. 303-311

Online Resource

0020-7616

English

Informa UK Limited

1983

1498203-1

12

Innovation in Aging, Oxford University Press (OUP), Vol. 1, No. suppl_1 ( 2017-07-01), p. 1307-1307

Online Resource

2399-5300

English

Oxford University Press (OUP)

2017

2905697-4

Innovation in Aging, Oxford University Press (OUP), Vol. 3, No. Supplement_1 ( 2019-11-08), p. S228-S229

There is a growing interest among aging services providers to better understand the pathways through which older adults and their caregivers navigate LTSS. Although there have been attempts at modeling this process they are often dependent on the quality of existing data, which can result in models which are incomplete and study samples that homogenize diverse older adult populations. These models face two challenges – 1) the data may not include information about important elements of the LTSS navigation process, and 2) the actions of ethnic/cultural sub-groups may not be captured. This study uses a conceptual method called Social Interaction Modeling (SIM) to examine how older adults in two limited English-speaking communities (Spanish / Mandarin Chinese) navigate the use of LTSS and to evaluate disparities in service access. The findings will help to build a more comprehensive model which looks at service navigation among all older adults in Philadelphia.

Online Resource

2399-5300

English

Oxford University Press (OUP)

2019

2905697-4